ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Aucubin inhibits epithelial-mesenchymal transition and angiogenesis in colorectal cancer via the HDAC6/PI3K/Akt signaling pathway.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer (CRC) represents a prevalent malignancy worldwide, with its high incidence and mortality rates necessitating novel therapeutic strategies. Aucubin (AU), a natural compound, has demonstrated diverse biological activities, yet its role and mechanisms in CRC remain incompletely understood. The effects of AU on the malignant biological behaviors of CRC were evaluated by CCK-8 assay, colony formation, Transwell, tube formation, wound healing, and flow cytometry experiments. ELISA quantification of angiogenic markers (MMP-2, MMP-9, VEGFA), immunofluorescence detection of epithelial-mesenchymal transition (EMT) markers (E-cadherin/N-cadherin) and key pathway protein (HDAC6), alongside Western blot assessment of EMT-related proteins, angiogenesis factors, and HDAC6/PI3K/Akt pathway components (HDAC6, p-PI3K/PI3K, p-AKT/AKT). Mechanistic investigations employed HDAC6-overexpressing and knockdown cell models. In vivo, HCT116 xenograft models were established for tumor volume/weight measurements, immunohistochemistry, HE staining, TUNEL assays, and Western blot validation. In vitro, AU significantly suppressed HCT116/SW620 cell proliferation, migration, and invasion while promoting apoptosis. AU reversed EMT phenotypes via E-cadherin upregulation and N-cadherin/Vimentin/Snail downregulation, concurrently inhibiting MMP-2/9 activity. AU impaired HUVEC tube formation and reduced VEGFA/FGF2/PDGF-BB expression. Mechanistically, AU inhibited HDAC6 expression and PI3K/Akt phosphorylation. HDAC6 overexpression partially rescued AU's effects, whereas HDAC6 knockdown potentiated them. In vivo results corroborated these findings, showing suppressed tumor growth, reduced Ki-67 expression, improved histopathology, enhanced apoptosis, and modulated expression of EMT/angiogenesis/HDAC6/PI3K/Akt pathway proteins. This study demonstrates that AU exerts antitumor effects by suppressing EMT and angiogenesis through HDAC6/PI3K/Akt pathway inhibition. Clinical trial number: not applicable.
Indexed as
Identifiers
41999432What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.